SABCS 2023 HR+/HER2- MBC

The development of action plans by providers and use of educational sessions found to improve patient compliance with oral oncolytics for those with HR+/HER2− breast cancer. Read More ›

Real-world analysis finds a preference shift from palbociclib to ribociclib and no significant differences in time to next treatment or time to treatment discontinuation for patients with HR+/HER-metastatic breast cancer. Read More ›

Study finds that patients with ER+/HER2− metastatic breast cancer who have prior CDK4/6 inhibitor treatment have a greater PFS when treated with elacestrant compared to standard of care. Read More ›

Oncology nurse navigators who work with younger patients with breast cancer and patients with metastatic breast cancer report barriers to services, information, and referrals. Read More ›

An algorithm of composite biomarkers and pathological variables is associated with predicting progression-free survival and overall survival in patients with HR+/HER2-metastatic breast cancer. Read More ›

Study finds older women with metastatic breast cancer in Nigeria benefit from belonging to a peer support group. Read More ›

Recent study results find mutations in the ESR1 gene directly promote resistance to CDK4/6 inhibitors used alone or in combination with antiestrogens. Read More ›

Recent analysis finds that Black and younger patients with metastatic breast cancer are more likely to receive chemotherapy first-line and less likely to receive CDK4/6 inhibitors when receiving endocrine therapy. Read More ›

Qualitative study finds the presence of children or grandchildren is a primary treatment decision factor for women with metastatic breast cancer. Read More ›